JP2015517801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517801A5 JP2015517801A5 JP2014561056A JP2014561056A JP2015517801A5 JP 2015517801 A5 JP2015517801 A5 JP 2015517801A5 JP 2014561056 A JP2014561056 A JP 2014561056A JP 2014561056 A JP2014561056 A JP 2014561056A JP 2015517801 A5 JP2015517801 A5 JP 2015517801A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- markers
- pervasive developmental
- developmental disorder
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 95
- 208000029560 autism spectrum disease Diseases 0.000 claims description 85
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 83
- 239000012472 biological sample Substances 0.000 claims description 34
- 239000003550 marker Substances 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 15
- 239000013068 control sample Substances 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 102000023732 binding proteins Human genes 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 208000036640 Asperger disease Diseases 0.000 claims description 2
- 201000006062 Asperger syndrome Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 206010050337 Cerumen impaction Diseases 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000002939 cerumen Anatomy 0.000 claims description 2
- 210000003756 cervix mucus Anatomy 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 210000001268 chyle Anatomy 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 210000003060 endolymph Anatomy 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 210000004211 gastric acid Anatomy 0.000 claims description 2
- 210000004251 human milk Anatomy 0.000 claims description 2
- 235000020256 human milk Nutrition 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 210000004912 pericardial fluid Anatomy 0.000 claims description 2
- 210000004049 perilymph Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 206010046901 vaginal discharge Diseases 0.000 claims description 2
- 210000004127 vitreous body Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- -1 hnRNA Proteins 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606935P | 2012-03-05 | 2012-03-05 | |
| US61/606,935 | 2012-03-05 | ||
| PCT/US2013/029201 WO2013134315A1 (en) | 2012-03-05 | 2013-03-05 | Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072819A Division JP2018153184A (ja) | 2012-03-05 | 2018-04-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517801A JP2015517801A (ja) | 2015-06-25 |
| JP2015517801A5 true JP2015517801A5 (enExample) | 2016-04-21 |
Family
ID=49117277
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561056A Pending JP2015517801A (ja) | 2012-03-05 | 2013-03-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
| JP2018072819A Pending JP2018153184A (ja) | 2012-03-05 | 2018-04-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
| JP2020137031A Pending JP2020193986A (ja) | 2012-03-05 | 2020-08-14 | 広汎性発達障害の診断および治療のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072819A Pending JP2018153184A (ja) | 2012-03-05 | 2018-04-05 | 広汎性発達障害の診断および治療のための組成物および方法 |
| JP2020137031A Pending JP2020193986A (ja) | 2012-03-05 | 2020-08-14 | 広汎性発達障害の診断および治療のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20150023949A1 (enExample) |
| EP (1) | EP2823063A4 (enExample) |
| JP (3) | JP2015517801A (enExample) |
| KR (1) | KR20140140069A (enExample) |
| CN (1) | CN104364393A (enExample) |
| AU (1) | AU2013230045A1 (enExample) |
| CA (1) | CA2866407A1 (enExample) |
| HK (1) | HK1206393A1 (enExample) |
| WO (1) | WO2013134315A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014024537A2 (pt) | 2012-04-02 | 2017-08-08 | Berg Llc | métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese |
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CN107111603A (zh) | 2014-09-11 | 2017-08-29 | 博格有限责任公司 | 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型 |
| BR112017024777A2 (pt) * | 2015-05-22 | 2018-08-07 | Univ Arizona State | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? |
| WO2017171842A1 (en) | 2016-04-01 | 2017-10-05 | Intel Corporation | Transistor cells including a deep via lined with a dielectric material |
| US10650621B1 (en) | 2016-09-13 | 2020-05-12 | Iocurrents, Inc. | Interfacing with a vehicular controller area network |
| CN106885858A (zh) * | 2017-03-10 | 2017-06-23 | 方雷 | 一种高效的痕量临床病人样本的高通量全蛋白组学定量分析方法 |
| CN107312846A (zh) * | 2017-07-12 | 2017-11-03 | 北京赛尔维康生物医学科技有限公司 | Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用 |
| CN109212226B (zh) * | 2018-09-06 | 2021-04-06 | 中国人民解放军联勤保障部队第九〇四医院 | 预测急性高山病发病风险的血浆蛋白标志物及其在制备诊断ams易感性试剂盒中的应用 |
| CN109239334A (zh) * | 2018-09-10 | 2019-01-18 | 吉林大学 | 建立时间分辨荧光免疫层析法检测MxA试剂盒 |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| WO2020215043A1 (en) * | 2019-04-19 | 2020-10-22 | Yale University | Advanced glycation end-product breaking biocatalysts |
| KR102158009B1 (ko) * | 2019-06-13 | 2020-09-21 | 고려대학교 산학협력단 | 주의력 결핍/과잉행동장애 진단용 마커로서의 14-3-3γ의 용도 |
| CN112442527B (zh) * | 2019-08-27 | 2022-11-11 | 深圳市英马诺生物科技有限公司 | 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用 |
| EP4348265A2 (en) * | 2021-05-25 | 2024-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnosis of autism spectrum disorder by multiomics platform |
| ES2976116A1 (es) * | 2023-12-15 | 2024-07-23 | Chrmtx Sl | Biomarcadores nucleares de la enfermedad de Alzheimer (EA), sus usos y métodos |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745149A4 (en) * | 2004-04-15 | 2008-08-06 | Univ Florida | NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS |
| GB0419124D0 (en) * | 2004-08-27 | 2004-09-29 | Proteome Sciences Plc | Methods and compositions relating to Alzheimer's disease |
| EP1842147A2 (en) * | 2005-01-24 | 2007-10-10 | The Board of Trustees of The Leland Stanford Junior University | Method for modeling cell signaling systems by means of bayesian networks |
| EP1840574A1 (en) * | 2006-03-30 | 2007-10-03 | Institut Pasteur | Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases |
| US20090117562A1 (en) * | 2007-04-09 | 2009-05-07 | Valerie Wailin Hu | Method and kit for diagnosing Autism using gene expression profiling |
| AU2009217278B2 (en) * | 2008-02-20 | 2015-08-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| US8173369B2 (en) * | 2008-05-15 | 2012-05-08 | The Regents Of The University Of California | Peripheral gene expression biomarkers for autism |
| US20110294693A1 (en) * | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| US20120178637A1 (en) * | 2009-07-07 | 2012-07-12 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
| EP2476053A4 (en) * | 2009-09-08 | 2014-03-12 | Nodality Inc | ANALYSIS OF CELL NETWORKS |
| US20130123124A1 (en) * | 2010-03-12 | 2013-05-16 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
| MX358408B (es) * | 2011-03-02 | 2018-08-20 | Berg Llc | Ensayos interrogatorios basados en celulas y usos de los mismos. |
| CN104487842B (zh) * | 2012-05-22 | 2017-09-08 | 博格有限责任公司 | 用于鉴别药物诱导毒性标志物的基于细胞的探询式分析 |
-
2013
- 2013-03-05 HK HK15106693.0A patent/HK1206393A1/xx unknown
- 2013-03-05 CN CN201380022420.3A patent/CN104364393A/zh active Pending
- 2013-03-05 CA CA2866407A patent/CA2866407A1/en not_active Abandoned
- 2013-03-05 WO PCT/US2013/029201 patent/WO2013134315A1/en not_active Ceased
- 2013-03-05 AU AU2013230045A patent/AU2013230045A1/en not_active Abandoned
- 2013-03-05 KR KR20147028035A patent/KR20140140069A/ko not_active Withdrawn
- 2013-03-05 JP JP2014561056A patent/JP2015517801A/ja active Pending
- 2013-03-05 US US14/383,450 patent/US20150023949A1/en not_active Abandoned
- 2013-03-05 EP EP13758001.5A patent/EP2823063A4/en not_active Withdrawn
-
2017
- 2017-12-04 US US15/830,982 patent/US20180275146A1/en not_active Abandoned
-
2018
- 2018-04-05 JP JP2018072819A patent/JP2018153184A/ja active Pending
-
2019
- 2019-02-14 US US16/275,944 patent/US20190242909A1/en not_active Abandoned
-
2020
- 2020-08-14 JP JP2020137031A patent/JP2020193986A/ja active Pending
-
2021
- 2021-06-11 US US17/346,152 patent/US20220137070A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517801A5 (enExample) | ||
| JP2014509515A5 (enExample) | ||
| JP2019150027A5 (enExample) | ||
| JP6401702B2 (ja) | 炎症性肝疾患の診断のための方法および組成物 | |
| JP7174385B2 (ja) | 膵臓がんを診断するためのラミニン２の使用 | |
| JP2018153184A5 (enExample) | ||
| JP2015503920A (ja) | 乳癌の予測および診断のためのバイオマーカー | |
| CA2792163A1 (en) | Biomarkers of osteoarthritis | |
| KR102185987B1 (ko) | Ripk3을 포함하는 당뇨병성 신증 진단용 바이오마커 및 이의 용도 | |
| JP6732914B2 (ja) | トリプトファニルｔＲＮＡ合成酵素を利用した感染症又は感染合併症の診断用組成物と診断マーカー検出方法 | |
| CN103898205A (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
| JP2016536585A (ja) | 膀胱癌バイオマーカー | |
| JP2012507030A5 (enExample) | ||
| WO2015182580A1 (ja) | 大腸がんの転移検出方法 | |
| WO2017039359A1 (ko) | 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법 | |
| CN104160039A (zh) | 川崎病的生物标志物 | |
| JP2018205327A (ja) | 子癇前症を診断するための方法および組成物 | |
| JP6800208B2 (ja) | 肝細胞増殖因子（ｈｇｆ）のｐｄマーカー | |
| CN107255711A (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
| JP2019516104A (ja) | 子宮内膜がんのマーカーとしてのｍｍｐ９ | |
| US20160244835A1 (en) | Urinary neuropilin-1 (nrp-1) as a prognostic marker for nephritis and lupus nephritis | |
| EP3428648B1 (en) | Method for assisting prediction of recurrence risk in hepatocellular carcinoma patient, and use of a kit | |
| JP7431226B2 (ja) | レンバチニブ及びエベロリムスを含む併用療法のためのバイオマーカー | |
| TWI842716B (zh) | 泌尿道上皮細胞癌生物標記及其應用 | |
| US20190033322A1 (en) | Detection and treatment of il-17 and il-13 related conditions |